|
Sep 24
|
Milestone Pharmaceuticals to Host Investor KOL Event
|
|
Sep 6
|
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
|
|
Aug 26
|
Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024
|
|
May 22
|
Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness
|
|
May 16
|
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know
|
|
May 13
|
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
|
|
May 2
|
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
|
|
Apr 17
|
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
|
|
Apr 8
|
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
|
|
Apr 3
|
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
|
|
Apr 1
|
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
|
|
Mar 28
|
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
|
|
Mar 21
|
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
|
|
Jan 16
|
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround
|
|
Dec 27
|
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
|
|
Aug 10
|
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
|
|
Aug 8
|
2 ‘Strong Buy’ Penny Stocks That Could Rally All the Way to $10 (or More)
|